Mutant smoothened and methods of using the same
Inventors
de Sauvage, Frederic J. • YAUCH, ROBERT L. • Dijkgraaf, Gerrit J. P. • Sharpe, Hayley • BASSET-SEGUIN, Nicole
Assignees
Assistance Publique - Hôpitaux de Paris • Université Paris Cité • Genentech Inc • Curis Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, mutations in the serpentine receptor, Smoothened (SMO) are described, which result in resistance to a Hedgehog (Hh) pathway inhibitor, such as in medulloblastoma. Amino acid substitutions in conserved residues of SMO maintain Hh signaling, but result in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. In some embodiments, the disclosure provides for novel mutant SMO proteins and nucleic acids and for screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
Core Innovation
The disclosed subject matter relates to isolated mutant SMO (Smoothened) proteins and methods and materials for hedgehog pathway inhibition in the presence of activating or increased hedgehog signaling mutations in SMO. The mutant SMO proteins are defined by specific amino-acid sequence requirements relative to SEQ ID NO: 6 and SEQ ID NO: 8, including an amino acid other than threonine at amino acid 241 and an amino acid other than cysteine at amino acid 469.
The mutant SMO proteins are described as constitutively active, as transducing hedgehog signaling, and as having increased basal activity. The disclosure further states that the mutant SMO can bind Costal-2, and that hedgehog signaling is monitored via Gli activity, including Gli1 expression.
The disclosure also includes methods for screening hedgehog pathway inhibitors using binding activity and Gli-related readouts. It further includes antibodies that bind to mutant SMO and exhibit selective binding to mutant SMO versus wild-type SMO.
Claims Coverage
The claim set centers on mutant SMO defined by SEQ ID NO: 6 or SEQ ID NO: 8 plus explicit residue constraints, and on identifying inhibitors either by detecting compound binding to mutant SMO or by detecting Gli activity in cells expressing the mutant SMO.
Mutant SMO binding-detection screening for residue 241 constraint
A method of screening for compounds that inhibit signaling of a mutant SMO protein having an amino acid sequence of SEQ ID NO: 6 with an amino acid other than threonine at amino acid 241, comprising contacting the mutant SMO with a test compound and detecting binding of the compound to the mutant SMO, whereby binding indicates that the test compound is an inhibitor of mutant SMO.
Cell-based Gli activity screening for residue 241 constraint
A method of screening for compounds that inhibit signaling of a mutant SMO protein having an amino acid sequence of SEQ ID NO: 6 with an amino acid other than threonine at amino acid 241, comprising contacting a cell that expresses the mutant SMO with a test compound and detecting activity of Gli in the cell, whereby the presence of Gli activity indicates that the test compound is not an inhibitor of mutant SMO.
Mutant SMO binding-detection screening for residue 469 constraint
A method of screening for compounds that inhibit signaling of a mutant SMO protein having an amino acid sequence of SEQ ID NO: 8 with an amino acid other than cysteine at amino acid 469, comprising contacting the mutant SMO with a test compound and detecting binding of the compound to the mutant SMO, whereby binding indicates that the test compound is an inhibitor of mutant SMO.
Cell-based Gli activity screening for residue 469 constraint
A method of screening for compounds that inhibit signaling of a mutant SMO protein having an amino acid sequence of SEQ ID NO: 8 with an amino acid other than cysteine at amino acid 469, comprising contacting a cell that expresses the mutant SMO with a test compound and detecting activity of Gli in the cell, whereby the presence of Gli activity indicates that the test compound is not an inhibitor of mutant SMO.
Isolated mutant SMO proteins defined by SEQ ID NO: 6 or SEQ ID NO: 8 constraints
An isolated mutant SMO protein having the amino acid sequence of (a) SEQ ID NO: 6 with an amino acid other than threonine at amino acid 241, or (b) SEQ ID NO: 8 with an amino acid other than cysteine at amino acid 469.
The claim set centers on mutant SMO defined by SEQ ID NO: 6 or SEQ ID NO: 8 plus explicit residue constraints, and on identifying inhibitors either by detecting compound binding to mutant SMO or by detecting Gli activity in cells expressing the mutant SMO.
Stated Advantages
Binding of a test compound to mutant SMO indicates that the test compound is an inhibitor of mutant SMO.
Presence of Gli activity indicates that the test compound is not an inhibitor of mutant SMO.
Documented Applications
Screening compounds for inhibition of Hedgehog signaling mediated by mutant SMO proteins.
Diagnostic/probe-based detection of SMO mutations using nucleic acids and probes.
Use of mutant SMO as a diagnostic and therapeutic target.
Interested in licensing this patent?